Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium phenylbutyrate - Horizon Therapeutics

Next Previous
X
Search
Drug Profile

Sodium phenylbutyrate - Horizon Therapeutics

Alternative Names: Ammonaps; Buphenyl; CMK 304

Latest Information Update: 06 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ucyclyd Pharma
  • Developer CMIC; Swedish Orphan Biovitrum; Ucyclyd Pharma
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperammonaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia

Most Recent Events

  • 06 Nov 2020 Immedica in-license sodium phenylbutyrate in Japan from Horizon Therapeutics plc
  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 07 Dec 2016 Swedish Orphan Biovitrum obtains rights to distribute and market sodium phenylbutyrate in Europe, including United Kingdom, Germany, France, Italy and Spain

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top